Low physical activity in patients diagnosed with head and neck cancer.
accelerometer
head and neck cancer
physical activity
Journal
Laryngoscope investigative otolaryngology
ISSN: 2378-8038
Titre abrégé: Laryngoscope Investig Otolaryngol
Pays: United States
ID NLM: 101684963
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
06
02
2021
revised:
19
05
2021
accepted:
18
06
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
This pilot study aimed to describe physical activity (PA) and self-perceived function, health and quality of life (QoL) prior to oncological treatment in patients with head and neck cancer (HNC). In a prospective study including 49 patients, self-perceived PA (Saltin-Grimby scale) and health-related QoL (European Organization for Research and Treatment of Cancer Quality of Life questionnaire Core 30 and EQ-5D) were assessed. Further, PA was also measured by an accelerometer attached to the thigh for eight consecutive days. The accelerometer PA was compared to the PA of a reference population assessed with the same method. Results presented are from data collected before start of oncological treatment. The patients (44-79 years, 65% males) spent most of their time in sedentary behavior: a median of 555 minutes/day in bed (39% of total) and 606 minutes/day sitting (41%). Only 129 minutes/day were spent moving/walking. Patients with higher education, reduced physical function and higher fatigue were less physically active ( Patients diagnosed for HNC may have low PA level. Assessment of PA from accelerometer data may be an important component of oncological treatment to identify patients in need for PA intervention that may enhance treatment outcome.
Sections du résumé
BACKGROUND
BACKGROUND
This pilot study aimed to describe physical activity (PA) and self-perceived function, health and quality of life (QoL) prior to oncological treatment in patients with head and neck cancer (HNC).
METHODS
METHODS
In a prospective study including 49 patients, self-perceived PA (Saltin-Grimby scale) and health-related QoL (European Organization for Research and Treatment of Cancer Quality of Life questionnaire Core 30 and EQ-5D) were assessed. Further, PA was also measured by an accelerometer attached to the thigh for eight consecutive days. The accelerometer PA was compared to the PA of a reference population assessed with the same method. Results presented are from data collected before start of oncological treatment.
RESULTS
RESULTS
The patients (44-79 years, 65% males) spent most of their time in sedentary behavior: a median of 555 minutes/day in bed (39% of total) and 606 minutes/day sitting (41%). Only 129 minutes/day were spent moving/walking. Patients with higher education, reduced physical function and higher fatigue were less physically active (
CONCLUSIONS
CONCLUSIONS
Patients diagnosed for HNC may have low PA level. Assessment of PA from accelerometer data may be an important component of oncological treatment to identify patients in need for PA intervention that may enhance treatment outcome.
Identifiants
pubmed: 34401499
doi: 10.1002/lio2.610
pii: LIO2610
pmc: PMC8356879
doi:
Types de publication
Journal Article
Langues
eng
Pagination
747-755Informations de copyright
© 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Health Promot. 2016 Jan-Feb;30(3):155-62
pubmed: 25806568
Sensors (Basel). 2019 Aug 01;19(15):
pubmed: 31374854
J Intern Med. 2019 Aug;286(2):137-153
pubmed: 30993807
J Natl Cancer Inst. 2018 Nov 1;110(11):1190-1200
pubmed: 30299508
Acta Oncol. 2020 Mar;59(3):342-350
pubmed: 31608747
Sports Med. 2017 Sep;47(9):1821-1845
pubmed: 28303543
Cancer. 2016 Apr 15;122(8):1185-200
pubmed: 26828426
Eur J Oncol Nurs. 2009 Apr;13(2):116-21
pubmed: 19230768
BMC Public Health. 2015 Sep 28;15:978
pubmed: 26415512
BMC Public Health. 2019 Oct 24;19(1):1370
pubmed: 31651272
J Clin Med. 2021 Feb 18;10(4):
pubmed: 33670615
Scand J Med Sci Sports. 2015 Dec;25 Suppl 4:119-25
pubmed: 26589125
Growth Horm IGF Res. 2020 Apr;51:27-33
pubmed: 32007834
J Phys Act Health. 2014 Jan;11(1):76-84
pubmed: 23249722
Acta Oncol. 2013 Oct;52(7):1543-51
pubmed: 23964657
Clin Otolaryngol. 2016 Jun;41(3):241-8
pubmed: 26212795
Br J Sports Med. 2016 Mar;50(6):325-38
pubmed: 25966911
BMJ. 2009 Oct 13;339:b3410
pubmed: 19826172
Br J Sports Med. 2018 Apr;52(8):505-513
pubmed: 28954800
Oral Oncol. 2021 Jun;117:105253
pubmed: 33901767
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Support Care Cancer. 2020 Aug;28(8):3701-3709
pubmed: 31820127
Head Neck. 2016 Apr;38 Suppl 1:E1086-96
pubmed: 26445898
Scand J Public Health. 2014 May;42(3):255-62
pubmed: 24311536
Eur J Clin Nutr. 2015 Jul;69(7):850-5
pubmed: 25351651
J Clin Oncol. 2009 Apr 20;27(12):1969-75
pubmed: 19289626
Sensors (Basel). 2019 May 11;19(9):
pubmed: 31083538
BMC Public Health. 2012 Aug 24;12:693
pubmed: 22920914
Eur J Surg Oncol. 2019 Nov;45(11):2045-2051
pubmed: 31217078
Support Care Cancer. 2006 Oct;14(10):1012-9
pubmed: 16538497
Oral Oncol. 2010 Oct;46(10):712-9
pubmed: 20850371